INNOVADERM CRO IS NOW INDERO.
READ THE ANNOUNCEMENT
Talk to us

Updates on Chronic Spontaneous Urticaria

Dr. April Armstrong

Dr. April Armstrong

Professor & Chief of Dermatology at University of California Los Angeles

Picture of 18229

18229

Indero was thrilled to mark its 25th anniversary with a special edition of our Breakfast Event at AAD 2025. Attendees joined us for Itch Insights: Hives & Highlights, where we delved into the latest insights and highlights on urticaria.

Event Highlights:

  • Explored Urticaria’s Unmet Needs: Participants gained a deeper understanding of the areas in urticaria care that require more attention and innovation.
  • Discovered Pathophysiology Updates: Attendees stayed updated on the latest research and developments in the pathophysiology of urticaria.
  • Role of Dermatologists in Clinical Trials: The event highlighted the crucial role dermatologists play in managing urticaria clinical trials.

We were honored to have April Armstrong, MD, MPH, Professor & Chief of Dermatology at University of California Los Angeles present on Updates on Chronic Spontaneous Urticaria.

Watch the video of April Armstrong’s presentation here:

Related Video

Watch “Updates on Chronic Inducible Urticaria”

Watch “Challenges of Managing Clinical Trials in Urticaria in 2025“

SHARE THIS POST

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.
Talk to us

Jeff Smith

Chef de la direction
Linkedin

Jeff Smith, Chef de la direction d’Indero Recherches, apporte près de 30 ans d’expérience dans l’industrie pharmaceutique et CRO, s’étant distingué par son leadership exceptionnel, sa vision stratégique et son innovation. L’expertise de Jeff couvre des opérations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matière de création de valeur, de gestion des partenaires et d’opérations CRO ont toujours contribué au succès dans ses fonctions précédentes. Sous la direction de Jeff, Indero continue d’étendre ses capacités, faisant progresser les connaissances médicales et les nouvelles thérapies en dermatologie et en rhumatologie.

Revolutionize Your Topical Trials

Efficacy insights in days, not months.

 Indero’s Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8–12 weeks to ≤3 days, and lowers costs, helping teams make informed go/no-go decisions faster.
LEARN MORE >